Share this video  

WCLC 2021 | Advances in perioperative immunotherapy in lung cancer

Rapid advances are being made with increasing investigation into the use of immunotherapy in the perioperative setting. Numerous Phase II trials are underway, including the large LCMC3 study of immune checkpoint inhibitor monotherapy using adjuvant atezolizumab. Jay Lee, MD, UCLA Health, Los Angeles, CA, discusses how these are giving way to Phase III trials looking at immunotherapies in combination with platinum-based chemotherapies and what considerations need to be made in these investigations. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.


Advisory board: AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Novartis
Consultancy: Genentech/Roche
Steering committee: Genentech/Roche, Novartis
Research support: Merck